Fifth Third Bancorp Ligand Pharmaceuticals Inc Transaction History

Fifth Third Bancorp

  • $30.5 Billion
  • Q3 2025

A detailed history of Fifth Third Bancorp transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 145 shares of LGND stock, worth $29,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
145
Previous 118 22.88%
Holding current value
$29,124
Previous $13,000 92.31%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
BUY
$112.56 - $177.14 $3,039 - $4,782
27 Added 22.88%
145 $25,000
Q2 2025

Jul 15, 2025
SELL
$96.67 - $118.22 $676 - $827
-7 Reduced 5.6%
118 $13,000
Q1 2025

Apr 15, 2025
BUY
$105.14 - $122.23 $3,995 - $4,644
38 Added 43.68%
125 $13,000
Q4 2024

Jan 21, 2025
SELL
$99.95 - $129.9 $2,698 - $3,507
-27 Reduced 23.68%
87 $9,000
Q3 2024

Oct 17, 2024
BUY
$82.7 - $110.11 $413 - $550
5 Added 4.59%
114 $11,000
Q2 2024

Jul 22, 2024
BUY
$68.53 - $87.91 $753 - $967
11 Added 11.22%
109 $9,000
Q4 2023

Jan 19, 2024
SELL
$49.57 - $72.63 $2,726 - $3,994
-55 Reduced 35.95%
98 $6,000
Q3 2023

Oct 31, 2023
BUY
$58.86 - $72.67 $1,471 - $1,816
25 Added 19.53%
153 $9,000
Q2 2023

Jul 25, 2023
BUY
$69.53 - $79.33 $208 - $237
3 Added 2.4%
128 $9,000
Q1 2023

Apr 24, 2023
BUY
$65.67 - $77.08 $3,414 - $4,008
52 Added 71.23%
125 $9,000
Q4 2022

Jan 25, 2023
BUY
$61.72 - $96.74 $1,975 - $3,095
32 Added 78.05%
73 $0
Q3 2022

Oct 25, 2022
SELL
$0.01 - $107.56 $0 - $2,904
-27 Reduced 39.71%
41 $4,000
Q2 2022

Aug 04, 2022
BUY
$74.52 - $117.06 $1,341 - $2,107
18 Added 36.0%
68 $6,000
Q1 2022

Apr 19, 2022
SELL
$94.99 - $151.56 $461,746 - $736,733
-4,861 Reduced 98.98%
50 $6,000
Q4 2021

Feb 01, 2022
BUY
$127.69 - $165.85 $615,976 - $800,060
4,824 Added 5544.83%
4,911 $759,000
Q3 2021

Oct 15, 2021
SELL
$102.33 - $144.73 $15,144 - $21,420
-148 Reduced 62.98%
87 $12,000
Q2 2021

Aug 06, 2021
SELL
$113.03 - $155.64 $6,329 - $8,715
-56 Reduced 19.24%
235 $31,000
Q1 2021

May 07, 2021
SELL
$99.52 - $215.83 $26,273 - $56,979
-264 Reduced 47.57%
291 $44,000
Q4 2020

Feb 16, 2021
SELL
$80.55 - $106.05 $231,984 - $305,424
-2,880 Reduced 83.84%
555 $55,000
Q3 2020

Nov 09, 2020
SELL
$89.56 - $126.72 $110,517 - $156,372
-1,234 Reduced 26.43%
3,435 $327,000
Q2 2020

Aug 05, 2020
BUY
$68.28 - $123.65 $14,475 - $26,213
212 Added 4.76%
4,669 $522,000
Q1 2020

May 05, 2020
BUY
$63.37 - $107.88 $25,411 - $43,259
401 Added 9.89%
4,457 $324,000
Q4 2019

Feb 14, 2020
SELL
$96.94 - $113.59 $14,444 - $16,924
-149 Reduced 3.54%
4,056 $423,000
Q3 2019

Nov 14, 2019
BUY
$86.25 - $120.16 $50,025 - $69,692
580 Added 16.0%
4,205 $419,000
Q2 2019

Aug 07, 2019
BUY
$107.38 - $129.34 $29,636 - $35,697
276 Added 8.24%
3,625 $414,000
Q1 2019

May 14, 2019
BUY
$105.93 - $142.47 $16,842 - $22,652
159 Added 4.98%
3,349 $421,000
Q4 2018

Feb 14, 2019
BUY
$128.36 - $272.13 $101,019 - $214,166
787 Added 32.75%
3,190 $433,000
Q3 2018

Nov 14, 2018
SELL
$211.18 - $274.49 $134,310 - $174,575
-636 Reduced 20.93%
2,403 $660,000
Q2 2018

Aug 14, 2018
SELL
$150.77 - $207.98 $114,132 - $157,440
-757 Reduced 19.94%
3,039 $630,000
Q1 2018

May 15, 2018
SELL
$138.63 - $182.62 $140,848 - $185,541
-1,016 Reduced 21.11%
3,796 $627,000
Q4 2017

Feb 14, 2018
BUY
$128.36 - $147.04 $35,170 - $40,288
274 Added 6.04%
4,812 $659,000
Q3 2017

Nov 14, 2017
SELL
$120.91 - $137.94 $67,588 - $77,108
-559 Reduced 10.97%
4,538 $618,000
Q2 2017

Aug 11, 2017
BUY
N/A
5,097
5,097 $619,000

Others Institutions Holding LGND

# of Institutions
342
Shares Held
20.5M
Call Options Held
19K
Put Options Held
11.5K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $3.39B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email